13/03/2025 - Press release
A study led by the Hospital del Mar Research Institute has established the importance of immunoglobulin A, an antibody that is part of the immune system, in generating a response to pneumonia vaccines. Researchers have found that the absence of this antibody leads to an overgrowth of gut microbiota, triggering an excessive and sustained immune system response, which ultimately becomes exhausted and fails to respond effectively to vaccines. The study, published in Science Advances, opens the door to exploring the possibility of early immunoglobulin therapy administration to prevent this process and reduce the risk of potentially dangerous infections, even in at-risk individuals without a diagnosed immunodeficiency.
Més informació "The relationship between gut microbiota, immunoglobulin A, and vaccine efficacy"
24/02/25 - General information
Hospital del Mar and its research institute are part of this project, which aims to develop nanophotonic sensors for the diagnosis and clinical management of bacterial infections at the point of care. On February 14, Hospital del Mar hosted the fourth follow-up meeting of the PHITBAC project. This initiative is driven by a consortium with public and private participation to develop rapid tests for the swift detection of bacteria, their antibiotic resistance, and antibiotic levels in the blood, all based on nanophotonics. Rapid diagnosis of microorganisms that cause severe infections remains an unresolved challenge in infectious disease management, and immediate bedside monitoring of antibiotic levels in severe infections is an unmet need.
21/02/2025 - General information
Dr. Joaquim Gea, Emeritus Head of the Pulmonology Department and researcher at the Hospital del Mar Research Institute, has been appointed as the coordinator of two special issues of the journals Cells and International Journal of Molecular Science. His role will involve selecting both the topics and the authors of the articles to be featured in these issues.
04/12/2024 - General information
She will hold the position for two years and will be responsible for reviewing and supervising the evaluation processes of each call within her field at the agency. Dr. Esther Barreiro, an associate physician in the Pulmonology Service at Hospital del Mar and a researcher at its research institute, has been appointed as the coordinator in the field of medical and health sciences at the Agency for the Management of University and Research Grants (AGAUR).
14/11/2024 - General information
This is a body created to advise the government in this field. Dr. Albert Goday, emeritus section head of the Endocrinology and Nutrition Department at Hospital del Mar, researcher at its research institute, and associate professor of Medicine at UPF, has been appointed president of the Advisory Council on Diabetes in Catalonia. This council's role is to provide guidance to the government on diabetes, and it includes endocrinologists, family doctors, nurses, as well as patients and representatives from patient associations.
02/10/2024 - Press release
· Chronic obstructive pulmonary disease (COPD) patients who die had, years earlier, a higher presence of about thirty proteins in their blood related to inflammation and coagulation. · Detecting these proteins allows for a very accurate prediction of future mortality risk in patients with stable COPD, according to a multicenter pilot study led by Hospital del Mar, recently published in the journal Cells. · Researchers used various models to predict mortality risk through an AI-assisted program developed by the Biomedical Informatics Research Group at Pompeu Fabra University (UPF) and the Hospital del Mar Research Institute, one of which reached a precision level of 95%.
Més informació "Blood markers identified to predict long-term mortality in stable COPD patients"
23/07/2024 - Press release
Chest ultrasound enables quick and easy identification of patients who may have a worse prognosis due to pneumonia caused by SARS-CoV-2 infection. The published work is a collaboration between Hospital del Mar and Doctors Without Borders, published in the Journal of Clinical Medicine. This diagnostic tool, with proper training and access to portable ultrasound devices, is particularly useful in resource-limited countries due to its ease of bedside use.
11/03/2024 - Covid-19
This is revealed by a study at Hospital del Mar, which prospectively analyzed data from nearly 2,000 people followed at the center's Post-COVID Unit. The main risk factors for developing persistent COVID are obesity, asthma and the severity of the disease. Women are also at higher risk These results lead the authors of the study to consider antiviral treatment also for people with SARS-CoV-2 infection who meet these risk factors, even if they do not suffer from severe COVID.
Més informació "Treatment of COVID-19 with antivirals may protect from persistent COVID"
15/02/2024 - Press release
A study by Hospital del Mar and Hospital General de Catalunya shows that this new type of device is three times more effective than previous models in completely closing the aneurysm. Moreover, in a safe way. It is published in the Journal of Neurointerventional Surgery. The new generation of stents for the treatment of cerebral aneurysms is more effective and safer, according to a study by Hospital del Mar and Hospital General de Catalunya that has just been published in the Journal of Neurointerventional Surgery. In fact, they are three times more effective, with practically no complications.
Més informació "Efficacy of the new generation of stents to treat cerebral aneurysm validated"
14/02/2024 - Covid-19
It is a monoclonal antibody with prophylactic and therapeutic action, isolated from blood samples of a patient infected by SARS-CoV-2 during the first wave of the pandemic. The antibody has been designed and developed by researchers from the Hospital del Mar Research Institute, the IrsiCaixa AIDS Research Institute, the National Center for Biotechnology and the Center for Genomic Regulation. In addition, this new treatment has been patented pending commercial development. This new treatment has been patented pending commercial development. The results of the work have been published in the journal Nature Communications.
Més informació "New antibody blocks all SARS-CoV-2 variants in preclinical models"
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
